Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
Marc-Andrea BaertschJana SchlenzkaKatharina LisenkoJulia KrzykallaNatalia BeckerKatja WeiselRichard NoppeneyHans MartinHans W LindemannMathias HaenelAxel NogaiChristof ScheidHans SalwenderRoland FenkUllrich GraevenPeter ReimerMartin Schmidt-HieberMartin GoernerIngo G H Schmidt-WolfStefan KleinAnthony D HoHartmut GoldschmidtPatrick WuchterPublished in: European journal of haematology (2017)
These data proof feasibility of PBSC collection at relapse but emphasize the importance of collection and storage of additional PBSC transplants during first-line treatment when mobilization is more efficient and less toxic.
Keyphrases
- phase iii
- multiple myeloma
- open label
- clinical trial
- stem cells
- end stage renal disease
- phase ii
- chronic kidney disease
- double blind
- newly diagnosed
- ejection fraction
- acute lymphoblastic leukemia
- acute myeloid leukemia
- placebo controlled
- low dose
- high dose
- prognostic factors
- peritoneal dialysis
- free survival
- electronic health record
- patient reported outcomes
- hodgkin lymphoma
- big data